207 related articles for article (PubMed ID: 26050527)
1. Macyranones: Structure, Biosynthesis, and Binding Mode of an Unprecedented Epoxyketone that Targets the 20S Proteasome.
Keller L; Plaza A; Dubiella C; Groll M; Kaiser M; Müller R
J Am Chem Soc; 2015 Jul; 137(25):8121-30. PubMed ID: 26050527
[TBL] [Abstract][Full Text] [Related]
2. Epoxomicin and Eponemycin Biosynthesis Involves gem-Dimethylation and an Acyl-CoA Dehydrogenase-Like Enzyme.
Zettler J; Zubeil F; Kulik A; Grond S; Kaysser L
Chembiochem; 2016 May; 17(9):792-8. PubMed ID: 26789439
[TBL] [Abstract][Full Text] [Related]
3. Cystomanamides: structure and biosynthetic pathway of a family of glycosylated lipopeptides from myxobacteria.
Etzbach L; Plaza A; Garcia R; Baumann S; Müller R
Org Lett; 2014 May; 16(9):2414-7. PubMed ID: 24735013
[TBL] [Abstract][Full Text] [Related]
4. Systematic Analyses of Substrate Preferences of 20S Proteasomes Using Peptidic Epoxyketone Inhibitors.
Huber EM; de Bruin G; Heinemeyer W; Paniagua Soriano G; Overkleeft HS; Groll M
J Am Chem Soc; 2015 Jun; 137(24):7835-42. PubMed ID: 26020686
[TBL] [Abstract][Full Text] [Related]
5. Identifying the Minimal Enzymes Required for Biosynthesis of Epoxyketone Proteasome Inhibitors.
Liu J; Zhu X; Zhang W
Chembiochem; 2015 Dec; 16(18):2585-9. PubMed ID: 26477320
[TBL] [Abstract][Full Text] [Related]
6. Multiplexed metagenome mining using short DNA sequence tags facilitates targeted discovery of epoxyketone proteasome inhibitors.
Owen JG; Charlop-Powers Z; Smith AG; Ternei MA; Calle PY; Reddy BV; Montiel D; Brady SF
Proc Natl Acad Sci U S A; 2015 Apr; 112(14):4221-6. PubMed ID: 25831524
[TBL] [Abstract][Full Text] [Related]
7. Potent proteasome inhibitors derived from the unnatural cis-cyclopropane isomer of Belactosin A: synthesis, biological activity, and mode of action.
Kawamura S; Unno Y; List A; Mizuno A; Tanaka M; Sasaki T; Arisawa M; Asai A; Groll M; Shuto S
J Med Chem; 2013 May; 56(9):3689-700. PubMed ID: 23547757
[TBL] [Abstract][Full Text] [Related]
8. Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening.
Di Giovanni C; Ettari R; Sarno S; Rotondo A; Bitto A; Squadrito F; Altavilla D; Schirmeister T; Novellino E; Grasso S; Zappalà M; Lavecchia A
Eur J Med Chem; 2016 Oct; 121():578-591. PubMed ID: 27318981
[TBL] [Abstract][Full Text] [Related]
9. Development and characterization of proteasome inhibitors.
Bo Kim K; Fonseca FN; Crews CM
Methods Enzymol; 2005; 399():585-609. PubMed ID: 16338383
[TBL] [Abstract][Full Text] [Related]
10. Cystargolides, 20S Proteasome Inhibitors Isolated from Kitasatospora cystarginea.
Gill KA; Berrué F; Arens JC; Carr G; Kerr RG
J Nat Prod; 2015 Apr; 78(4):822-6. PubMed ID: 25769015
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome.
Xu K; Wang K; Yang Y; Yan DA; Huang L; Chen CH; Xiao Z
Eur J Med Chem; 2015 Jun; 98():61-8. PubMed ID: 26005024
[TBL] [Abstract][Full Text] [Related]
12. α- and β-hydrazino acid-based pseudopeptides inhibit the chymotrypsin-like activity of the eukaryotic 20S proteasome.
Bordessa A; Keita M; Maréchal X; Formicola L; Lagarde N; Rodrigo J; Bernadat G; Bauvais C; Soulier JL; Dufau L; Milcent T; Crousse B; Reboud-Ravaux M; Ongeri S
Eur J Med Chem; 2013; 70():505-24. PubMed ID: 24185380
[TBL] [Abstract][Full Text] [Related]
13. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome.
Desvergne A; Genin E; Maréchal X; Gallastegui N; Dufau L; Richy N; Groll M; Vidal J; Reboud-Ravaux M
J Med Chem; 2013 Apr; 56(8):3367-78. PubMed ID: 23540790
[TBL] [Abstract][Full Text] [Related]
14. Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors.
Zhuang R; Gao L; Lv X; Xi J; Sheng L; Zhao Y; He R; Hu X; Shao Y; Pan X; Liu S; Huang W; Zhou Y; Li J; Zhang J
Eur J Med Chem; 2017 Jan; 126():1056-1070. PubMed ID: 28027531
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
Zhang J; Cao J; Xu L; Zhou Y; Liu T; Li J; Hu Y
Bioorg Med Chem; 2014 Jun; 22(11):2955-65. PubMed ID: 24767818
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach.
Groll M; Huber R
Biochim Biophys Acta; 2004 Nov; 1695(1-3):33-44. PubMed ID: 15571807
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive mass spectrometric analysis of the 20S proteasome complex.
Huang L; Burlingame AL
Methods Enzymol; 2005; 405():187-236. PubMed ID: 16413316
[TBL] [Abstract][Full Text] [Related]
19. Peptido sulfonyl fluorides as new powerful proteasome inhibitors.
Brouwer AJ; Jonker A; Werkhoven P; Kuo E; Li N; Gallastegui N; Kemmink J; Florea BI; Groll M; Overkleeft HS; Liskamp RM
J Med Chem; 2012 Dec; 55(24):10995-1003. PubMed ID: 23170994
[TBL] [Abstract][Full Text] [Related]
20. Indolo-phakellins as β5-specific noncovalent proteasome inhibitors.
Beck P; Lansdell TA; Hewlett NM; Tepe JJ; Groll M
Angew Chem Int Ed Engl; 2015 Feb; 54(9):2830-3. PubMed ID: 25581903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
